

CITATION REPORT

List of articles citing

Eradication therapy in *Helicobacter pylori* positive peptic ulcer disease: systematic review and economic analysis

DOI: 10.1111/j.1572-0241.2004.40014.x

American Journal of Gastroenterology, 2004, 99, 1833-55.

Source: <https://exaly.com/paper-pdf/37356207/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
142	Helicobacter pylori public health implications. 2004 , 9 Suppl 1, 67-72		30
141	A new era for gastrointestinal research [Novel therapeutic targets for drug development]. 2004 , 4, 535-537		
140	Peptic ulcer and Helicobacter pylori: update on testing and treatment. 2005 , 117, 17-22, 46		4
139	Treatment of Helicobacter pylori. 2005 , 10 Suppl 1, 40-6		60
138	Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?. 2005 , 21, 795-804		46
137	Update on Therapeutic Options for Helicobacter pylori-related Diseases. 2005 , 7, 115-120		21
136	Science, politics, and the regulation of dietary supplements: it's time to repeal DSHEA. 2005 , 31, 175-214		12
135	Economic evaluation of treatment strategies in gastroenterology. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2143-5	0.7	4
134	A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. 2005 , 129, 1910-7		48
133	Acid suppression therapy: where do we go from here?. 2006 , 24, 11-46		64
132	Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. 2006 , 126-127, 250-7		84
131	The role of psychosocial factors in peptic ulcer disease: beyond Helicobacter pylori and NSAIDs. 2006 , 60, 407-12		53
130	[Vaccines under development: Helicobacter pylori]. 2006 , 23, 249-56		3
129	Pharmacoeconomic comparison of Helicobacter pylori eradication regimens. 2006 , 28, 207-14		8
128	Can the clinical history distinguish between organic and functional dyspepsia?. 2006 , 295, 1566-76		115
127	Eradication of Helicobacter pylori: are rifaximin-based regimens effective?. 2006 , 73 Suppl 1, 129-35		21
126	Physiological Basis of Aging and Geriatrics. 2007 ,		22

125	American College of Gastroenterology guideline on the management of <i>Helicobacter pylori</i> infection. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1808-25	0.7	957
124	Eradication therapy for <i>Helicobacter pylori</i> . 2007 , 133, 985-1001		179
123	Gastrointestinal Regenerative Engineering. 798-818		
122	<i>Helicobacter pylori</i> as a class I carcinogen: physiopathology and management strategies. 2007 , 102, 264-73		33
121	Treatment of <i>Helicobacter pylori</i> . 2007 , 21, 315-24		59
120	The health economics of <i>Helicobacter pylori</i> infection. 2007 , 21, 347-61		20
119	Short-term triple therapy with azithromycin for <i>Helicobacter pylori</i> eradication: low cost, high compliance, but low efficacy. 2008 , 8, 20		7
118	Eradicating <i>Helicobacter pylori</i> in peptic ulcer disease reduces medical costs in the community. 2008 , 13, 346-51		3
117	<i>Helicobacter Pylori</i> Infection in the Elderly. 2008 , 2, 145-153		3
116	<i>Helicobacter pylori</i> test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). 2008 , 336, 651-4		61
115	Eradication of <i>helicobacter pylori</i> to prevent gastroduodenal diseases: hitting more than one bird with the same stone. 2008 , 1, 111-20		12
114	<i>Helicobacter pylori</i> eradication therapy: indications, efficacy and safety. 2008 , 7, 271-81		19
113	Stomach and Duodenum. 2008 , 841-874		
112	<i>Helicobacter pylori</i> binding to new glycans based on N-acetyllactosamine. 2009 , 19, 399-407		11
111	Treatment of <i>Helicobacter pylori</i> infection. 2008 , 337, a1454		29
110	Adverse events with bismuth salts for <i>Helicobacter pylori</i> eradication: systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2008 , 14, 7361-70	5.6	85
109	S3-guideline "helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. 2009 , 47, 1230-63		48
108	[S3-guideline " <i>Helicobacter pylori</i> and gastroduodenal ulcer disease"]. 2009 , 47, 68-102		56

107	Assessing the risks and benefits of treating <i>Helicobacter pylori</i> infection. 2009 , 2, 141-7		16
106	Managing dyspepsia. 2009 , 11, 288-94		8
105	Pylera for the eradication of <i>Helicobacter pylori</i> infection. <i>Expert Review of Anti-Infective Therapy</i> , 2009 , 7, 793-9	5.5	18
104	Guidelines for the management of <i>Helicobacter pylori</i> infection in Japan: 2009 revised edition. 2010 , 15, 1-20		355
103	Cost-effectiveness of six strategies for <i>Helicobacter pylori</i> diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern. 2010 , 10, 344		15
102	Effect of hydrodistillation with phosphoric acid on the yield of Chios mastic gum essential oil. 2010 , 25, 48-53		5
101	Peptic Ulcer Disease. 2010 , 325-335		
100	Intestinal metaplasia -the effect of Acid on the gastric mucosa and gastric carcinogenesis-. 2010 , 23, 115-23		6
99	Empiric quadruple vs. triple therapy for primary treatment of <i>Helicobacter pylori</i> infection: Systematic review and meta-analysis of efficacy and tolerability. <i>American Journal of Gastroenterology</i> , 2010 , 105, 65-73	0.7	149
98	Immunoglobulin G antibody against <i>Helicobacter pylori</i> is an accurate test for atrophic gastritis. 2010 , 73, 355-9		8
97	<i>Helicobacter pylori</i> eradication. 2011 , 378, 313; author reply 314		
96	How well is <i>Helicobacter pylori</i> treated in usual practice?. 2011 , 25, 543-6		7
95	Effect of <i>Helicobacter pylori</i> eradication therapy on risk of hospitalization for a major ulcer event. 2011 , 31, 239-47		8
94	A clinician's guide to salvage therapy for persistent <i>Helicobacter pylori</i> infection. 2011 , 39, 133-40		4
93	Healing effects of rebamipide and omeprazole in <i>Helicobacter pylori</i> -positive gastric ulcer patients after eradication therapy: a randomized double-blind, multinational, multi-institutional comparative study. 2011 , 84, 221-9		11
92	<i>Helicobacter pylori</i> DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis. <i>Gut</i> , 2011 , 60, 1479-86	19.2	74
91	The potential role of N-acetylcysteine for the treatment of <i>Helicobacter pylori</i> . 2011 , 45, 841-3		20
90	Dyspepsia. 2012 , 28, 602-7		14

89	A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan. 2012 , 51, 3103-8		6
88	No helicobacter left behind: detecting the infection in patients with partial gastrectomy. 2012 , 46, 257-8		
87	Treatment of Helicobacter pylori in Latin America. 2012 , 379, 407; author reply 408-9		
86	A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. 2012 , 47, 276-83	19	
85	Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. 2012 , 47, 394-403		84
84	Characterization of interleukin-1 β in Helicobacter pylori-induced gastric inflammation and DNA methylation in interleukin-1 receptor type 1 knockout (IL-1R1(-/-)) mice. 2013 , 49, 2760-70		34
83	Erosionen und Ulzera des Magens und Bulbus duodeni. 2013 , 191-199		
82	Histological examination of ulcer margin for diagnosing Helicobacter pylori infection in patients with gastric ulcers. 2013 , 17, 63-6		3
81	Dyspepsia. 2013 , 347, f5059		11
80	Proton Pump Inhibitors: Key Ingredients in Helicobacter pylori Eradication Treatment. 2013 , 59-67		3
79	Dyspepsia. 2013 , 29, 662-8		16
78	Helicobacter pylori infection in functional dyspepsia. 2013 , 10, 168-74		121
77	Optimum duration of regimens for Helicobacter pylori eradication. 2013 , CD008337		80
76	Probiotics as adjunctive therapy for eradication of Helicobacter pylori infection. 2013 ,		1
75	Efficacy and safety of herbal medicines in treating gastric ulcer: a review. <i>World Journal of Gastroenterology</i> , 2014 , 20, 17020-8	5.6	54
74	Approach to Helicobacter pylori infection in geriatric population. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014 , 5, 139-47	3	13
73	A win for the patient: Direct patient notification improves treatment rates of active Helicobacter pylori infection. 2014 , 7, 350-4		2
72	Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. <i>World Journal of Gastroenterology</i> , 2014 , 20, 5461-73	5.6	134

71	Whom should we "test and treat" for <i>Helicobacter pylori</i> ?. 2014 , 348, g3320	8
70	High risk of failing eradication of <i>Helicobacter pylori</i> in patients with diabetes: a meta-analysis. 2014 , 106, 81-7	28
69	A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of <i>Helicobacter pylori</i> Infection: A Pilot Study. 2015 , 20, 390-6	16
68	Review: Bismuth complexes: synthesis and applications in biomedicine. 2015 , 68, 379-397	81
67	Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses. 2015 , 16, 219-23	1
66	Long-Term Recurrence Rates of Peptic Ulcers without <i>Helicobacter pylori</i> . <i>Gut and Liver</i> , 2016 , 10, 719-25.8	15
65	Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. 2016 , 14, 179	181
64	Peptic Ulcer Disease. 2016 , 115-120	
63	Prospective identification of <i>Helicobacter pylori</i> in routine gastric biopsies without reflex ancillary stains is cost-efficient for our health care system. 2016 , 58, 90-96	4
62	Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of <i>Helicobacter pylori</i> Infection: Two Pilot Studies. 2016 , 21, 375-81	24
61	Evidence-based clinical practice guidelines for peptic ulcer disease 2015. 2016 , 51, 177-94	81
60	Management of <i>Helicobacter Pylori</i> in the United States: Results from a national survey of gastroenterology physicians. 2017 , 100, 216-222	18
59	Population screening and treatment of <i>Helicobacter pylori</i> infection. 2017 , 14, 230-240	96
58	Dietary habits and <i>Helicobacter pylori</i> infection: a cross sectional study at a Lebanese hospital. 2018 , 18, 48	15
57	Houston Consensus Conference on Testing for <i>Helicobacter pylori</i> Infection in the United States. 2018 , 16, 992-1002.e6	107
56	<i>Helicobacter pylori</i> and Other Gastritides. 2018 , 301-307	
55	<i>Helicobacter pylori</i> management in ASEAN: The Bangkok consensus report. 2018 , 33, 37-56	60
54	<i>Helicobacter pylori</i> -associated peptic ulcer disease: A retrospective analysis of post-treatment testing practices. 2018 , 23, e12540	5

53	Importance of timely eradication of <i>Helicobacter pylori</i> to prevent peptic ulcer recurrence and gastric cancer. 2018 , 88, 251-252		4
52	Association between parental history of <i>Helicobacter pylori</i> treatment failure and treatment failure in the offspring. 2019 , 34, 2112-2117		4
51	Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing <i>Helicobacter pylori</i> -associated diseases. 2019 , 24, e12563		14
50	Pylera [®] plus ranitidine vs Pylera [®] plus esomeprazole in first-line treatment of <i>Helicobacter pylori</i> infection: Two pilot studies. 2019 , 24, e12606		4
49	Reconciliation of Recent <i>Helicobacter pylori</i> Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. 2019 , 157, 44-53		116
48	Medical Management of Peptic Ulcer Disease. 2019 , 653-659		1
47	The cost effectiveness of <i>Helicobacter pylori</i> population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up. 2019 , 49, 1013-1025		10
46	The eradication of <i>Helicobacter pylori</i> to prevent gastric cancer: a critical appraisal. 2019 , 13, 17-24		25
45	What Would the Screen-and-Treat Strategy for <i>Helicobacter pylori</i> Mean in Terms of Antibiotic Consumption?. 2020 , 65, 1632-1642		2
44	Sequential <i>Helicobacter pylori</i> eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability. 2020 , 35, 617-623		7
43	In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of <i>Helicobacter pylori</i> collected in China. 2020 , 98, 115129		3
42	Telephone-Based Reeducation of Drug Administration for Eradication: A Multicenter Randomized Controlled Study. <i>Gastroenterology Research and Practice</i> , 2020 , 2020, 8972473	2	3
41	Duodenal Ulcer. 2020 , 90-102		
40	Role of vacuolating cytotoxin A in infection and its impact on gastric pathogenesis. <i>Expert Review of Anti-Infective Therapy</i> , 2020 , 18, 987-996	5.5	7
39	eradication therapy to prevent gastric cancer: systematic review and meta-analysis. <i>Gut</i> , 2020 , 69, 2113-2121	10	81
38	A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for <i>Helicobacter pylori</i> rescue treatment. <i>Journal of Digestive Diseases</i> , 2020 , 21, 256-263	3.3	4
37	Analysis of risk factors affecting the development of peptic ulcer perforation: case-control study. <i>Przegląd Gastroenterologiczny</i> , 2021 , 16, 23-28	6	1
36	Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. <i>Endoscopy</i> , 2021 , 53, 300-332	3.4	43

35	Molecular testing for H. pylori clarithromycin and quinolone resistance: a prospective Chinese study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 1599-1608	5.3	1
34	Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). <i>American Journal of Gastroenterology</i> , 2021 , 116, 1220-1229	0.7	15
33	Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis. <i>Advances in Therapy</i> , 2021 , 38, 3937-3947	4.1	0
32	Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. <i>Indian Journal of Gastroenterology</i> , 2021 , 40, 420-444	1.9	1
31	Considering global vaccination against Helicobacter pylori. <i>Southern Medical Journal</i> , 2010 , 103, 185-6	0.6	5
30	Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection. <i>PLoS ONE</i> , 2020 , 15, e0244500	3.7	2
29	Interleukin-17 levels in Helicobacter pylori-infected gastric mucosa and pathologic sequelae of colonization. <i>World Journal of Gastroenterology</i> , 2005 , 11, 6305-11	5.6	80
28	Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4386-90	5.6	17
27	Helicobacter pylori: friend or foe?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 8979-85	5.6	25
26	Hybrid Therapy versus Sequential Therapy for Eradication of : A Randomized Controlled Trial. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2017 , 8, 62-67	0.2	6
25	Endoscopic hemostasis techniques for upper gastrointestinal hemorrhage: A review. <i>World Journal of Gastrointestinal Endoscopy</i> , 2010 , 2, 54-60	2.2	7
24	Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori. <i>Gut and Liver</i> , 2012 , 6, 452-6	4.8	15
23	Helicobacter pylori Eradication Rate in Patients with Diabetes. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2017 , 17, 83	0.4	1
22	Diseases of the gastrointestinal system. 2007 , 229-297		
21	Treatment of Peptic Ulcer Disease. 2010 , 869-886.e4		
20	Management of Peptic Ulcer Disease. 2011 , 125-142		
19	Management of Helicobacter pylori Infection. 2011 , 89-124		0
18	Dyspepsia: Ulcer and Non-Ulcer/Bloating and Early Satiety/Belching and Rumination. 22-25		

17	Therapy for <i>H.</i> <i>pylori</i>; Current concepts. <i>Open Journal of Gastroenterology</i> , 2013 , 03, 38-41	0.2	
16	Furazolidone-Based Quadruple Therapy for Eradication of Helicobacter pylori Infection in Peptic Ulcer Disease. <i>Archives of Clinical Infectious Diseases</i> , 2014 , 9,	3.1	
15	Economic evaluations in gastroenterology in Brazil: A systematic review. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016 , 7, 162-70	3	1
14	Treating Helicobacter pylori infection in the face of growing antibiotic resistance. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 653-654	0.9	2
13	An Updated Approach to Evaluation and Treatment of Infection. <i>Southern Medical Journal</i> , 2019 , 112, 392-398	0.6	2
12	Psychosomatische Aspekte des peptischen Ulkusleidens. 2007 , 108-114		
11	Contemporary Diagnostic Strategies for the Detection of Helicobacter pylori Infection. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 1-16	0.7	1
10	Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial. <i>Journal of Medicine and Life</i> , 2014 , 7, 254-9	1.5	7
9	Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 1-19	0.7	1
8	Helicobacter pylori Infection in the Era of Antibiotic Resistance. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 122-5	0.7	4
7	Rallying Community Health Care Providers to Close the Gap Between H pylori Guidelines and the Challenges of Eradication. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 811-4	0.7	1
6	Efficacy of eradication therapy for functional dyspepsia: updated systematic review and meta-analysis.. <i>Gut</i> , 2022 ,	19.2	4
5	The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication: A multicenter, randomized, controlled clinical trial.. <i>Medicine (United States)</i> , 2021 , 100, e27923	1.8	0
4	British Society of Gastroenterology guidelines on the management of functional dyspepsia. <i>Gut</i> , gutjnl-2022-327737	0.7	0
3	Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China. 2022 , 19, 9986		0
2	Diseases of the Stomach. 2013 , 279-285.e1		0
1	A Malaysian consensus report on the diagnosis and treatment of Helicobacter pylori infection.		0